Roche licenses Alector's brain-penetrant Parkinson's therapy for up to $1.3B #$RHHBY #$ALEC firstwordpharma.com/story/8166685
October 5, 2026 at 10:37 PM
Roche licenses Alector's brain-penetrant Parkinson's therapy for up to $1.3B #$RHHBY #$ALEC firstwordpharma.com/story/8166685
Completed signal change · Stock · through 2026-09-30
RHHBY: Bullish → Neutral
https://www.marketsignalhub.com/signals/?chart=stock%3ARHHBY%3AUSD&range=1y&utm_source=bluesky&utm_medium=organic-social&utm_campaign=daily-signals
RHHBY: Bullish → Neutral
https://www.marketsignalhub.com/signals/?chart=stock%3ARHHBY%3AUSD&range=1y&utm_source=bluesky&utm_medium=organic-social&utm_campaign=daily-signals
October 1, 2026 at 8:11 PM
Completed signal change · Stock · through 2026-09-30
RHHBY: Bullish → Neutral
https://www.marketsignalhub.com/signals/?chart=stock%3ARHHBY%3AUSD&range=1y&utm_source=bluesky&utm_medium=organic-social&utm_campaign=daily-signals
RHHBY: Bullish → Neutral
https://www.marketsignalhub.com/signals/?chart=stock%3ARHHBY%3AUSD&range=1y&utm_source=bluesky&utm_medium=organic-social&utm_campaign=daily-signals
7/7 correlate with near-term pipeline pressure and renewed investor scrutiny of survival curves in the company's mid-stage portfolio. Full: https://insider.wizybit.com/blog/post?slug=rhhby-roche-faces-mixed-portfolio-signals-as-two-phase-2-trials-halt-2026-09-30
September 30, 2026 at 1:25 PM
7/7 correlate with near-term pipeline pressure and renewed investor scrutiny of survival curves in the company's mid-stage portfolio. Full: https://insider.wizybit.com/blog/post?slug=rhhby-roche-faces-mixed-portfolio-signals-as-two-phase-2-trials-halt-2026-09-30
1/7 🧬 $RHHBY Hoffmann-La Roche flagged a cluster of late-stage biotech catalysts over the past two weeks—and the pattern is decidedly mixed.
Read the full story
RHHBY: Roche Faces Mixed Portfolio Signals as Two Phase 2 Trials Halt
InsiderWatch | insider.wizybit.com
insider.wizybit.com
September 30, 2026 at 1:25 PM
1/7 🧬 $RHHBY Hoffmann-La Roche flagged a cluster of late-stage biotech catalysts over the past two weeks—and the pattern is decidedly mixed.
Zurich analyst: I watch $RHHBY (ROG.SW). Roche mounts a higher summit after IgAN P3 and Susvimo EU OK-EU upside mispriced. DCF implies 12m +20% ascent. https://www.clinicaltrialsarena.com/news/roche-targets-novartis-on-igan-market-after-phase-iii-win/
September 30, 2026 at 7:08 AM
Zurich analyst: I watch $RHHBY (ROG.SW). Roche mounts a higher summit after IgAN P3 and Susvimo EU OK-EU upside mispriced. DCF implies 12m +20% ascent. https://www.clinicaltrialsarena.com/news/roche-targets-novartis-on-igan-market-after-phase-iii-win/
Former Genentech scientists launch 'AI lab' newco with $500M #$RHHBY firstwordpharma.com/story/8120275
September 29, 2026 at 9:41 PM
Former Genentech scientists launch 'AI lab' newco with $500M #$RHHBY firstwordpharma.com/story/8120275
Roche charts path from AI-assisted research to lab autonomy #$RHHBY firstwordpharma.com/story/8114093
September 29, 2026 at 12:14 AM
Roche charts path from AI-assisted research to lab autonomy #$RHHBY firstwordpharma.com/story/8114093
Buy ROG.SW; $RHHBY undervalued after P3 IgAN win and Susvimo approval. Swiss-based view: Europe misprices regulatory upside - 12m target +20% as Roche completes ascent to summit. I use @bluestocks.app for analysi #finsky
September 28, 2026 at 7:06 AM
Buy ROG.SW; $RHHBY undervalued after P3 IgAN win and Susvimo approval. Swiss-based view: Europe misprices regulatory upside - 12m target +20% as Roche completes ascent to summit. I use @bluestocks.app for analysi #finsky
Zurich analysi: Roche via $RHHBY (ROG.SW) - EU ascent misprices; buy. https://www.investing.com/news/stock-market-news/roches-sefaxersen-shows-positive-results-in-kidney-disease-trial-93CH-4912083
September 26, 2026 at 2:07 PM
Zurich analysi: Roche via $RHHBY (ROG.SW) - EU ascent misprices; buy. https://www.investing.com/news/stock-market-news/roches-sefaxersen-shows-positive-results-in-kidney-disease-trial-93CH-4912083
Getting medicines into the brain: shuttles, vectors and direct delivery | #$DNLI, #$QURE, #$RHHBY, #$VYGR
www.merlintrader.com/brain-drug-d...
www.merlintrader.com/brain-drug-d...
September 26, 2026 at 10:38 AM
Getting medicines into the brain: shuttles, vectors and direct delivery | #$DNLI, #$QURE, #$RHHBY, #$VYGR
www.merlintrader.com/brain-drug-d...
www.merlintrader.com/brain-drug-d...
US approves Roche's Gazyva to prevent nephrotic syndrome relapses #$RHHBY firstwordpharma.com/story/8101685
September 26, 2026 at 12:03 AM
US approves Roche's Gazyva to prevent nephrotic syndrome relapses #$RHHBY firstwordpharma.com/story/8101685
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic.. statnews.com/pharmalot/20... #pharma #pandemic #flu #influenze #Roche #$RHHBY
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
With an eye toward pandemic preparedness, a U.N.-backed agency has signed sub-licensing deals related to generic versions of a Roche influenza treatment.
statnews.com
September 25, 2026 at 5:58 PM
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic.. statnews.com/pharmalot/20... #pharma #pandemic #flu #influenze #Roche #$RHHBY
Roche taps Earendil's AI tech for bispecific discovery in $1.5B deal #$RHHBY firstwordpharma.com/story/8095979
September 25, 2026 at 12:15 AM
Roche taps Earendil's AI tech for bispecific discovery in $1.5B deal #$RHHBY firstwordpharma.com/story/8095979
Swiss analysi: Roche via $RHHBY (ROG.SW) faces steep ascent; EU misprices upside, +15%. https://www.fiercepharma.com/pharma/roche-lunsumio-delivers-positive-confirmatory-trial-readout-follicular-lymphoma
September 24, 2026 at 7:08 AM
Swiss analysi: Roche via $RHHBY (ROG.SW) faces steep ascent; EU misprices upside, +15%. https://www.fiercepharma.com/pharma/roche-lunsumio-delivers-positive-confirmatory-trial-readout-follicular-lymphoma
Cue touts Phase II hives data for Xolair challenger, but shares tumble #$CUE #$RHHBY #$NVS firstwordpharma.com/story/8075269
September 21, 2026 at 10:11 PM
Cue touts Phase II hives data for Xolair challenger, but shares tumble #$CUE #$RHHBY #$NVS firstwordpharma.com/story/8075269
Zurich analysi: I watch Roche via $RHHBY; FDA priority lifts ROG.SW altitude. https://finance.yahoo.com/healthcare/articles/roche-genentech-gets-fda-priority-143530148.html
September 19, 2026 at 7:03 AM
Zurich analysi: I watch Roche via $RHHBY; FDA priority lifts ROG.SW altitude. https://finance.yahoo.com/healthcare/articles/roche-genentech-gets-fda-priority-143530148.html
6/6 The portfolio remains in active transition. Full: https://insider.wizybit.com/blog/post?slug=rhhby-s-pipeline-mix-clouds-as-hepatocellular-trial-halts-2026-09-16
September 16, 2026 at 1:25 PM
6/6 The portfolio remains in active transition. Full: https://insider.wizybit.com/blog/post?slug=rhhby-s-pipeline-mix-clouds-as-hepatocellular-trial-halts-2026-09-16
1/6 💊 $RHHBY Hoffmann-La Roche flagged a pivotal week in its oncology and specialty portfolio: InsiderWatch's biotech tracker surfaced six clinical-trial status updates spanning cancer, ophthalmology, and neurodegeneration, split between progress and setback.
Read the full story
RHHBY's Pipeline Mix Clouds as Hepatocellular Trial Halts
InsiderWatch | insider.wizybit.com
insider.wizybit.com
September 16, 2026 at 1:25 PM
1/6 💊 $RHHBY Hoffmann-La Roche flagged a pivotal week in its oncology and specialty portfolio: InsiderWatch's biotech tracker surfaced six clinical-trial status updates spanning cancer, ophthalmology, and neurodegeneration, split between progress and setback.
CH: I've been watching $RHHBY; Roche FDA wins raise ROG.SW altitude - EU ascent. https://finance.yahoo.com/healthcare/articles/roche-genentech-gets-fda-priority-143530148.html
September 16, 2026 at 7:07 AM
CH: I've been watching $RHHBY; Roche FDA wins raise ROG.SW altitude - EU ascent. https://finance.yahoo.com/healthcare/articles/roche-genentech-gets-fda-priority-143530148.html
Roche, MediLink's ADC boost survival in relapsed SCLC #$RHHBY #WCLC2026 firstwordpharma.com/story/7990444
September 15, 2026 at 4:36 AM
Roche, MediLink's ADC boost survival in relapsed SCLC #$RHHBY #WCLC2026 firstwordpharma.com/story/7990444
Swiss analyst: I track $RHHBY - Roche faces high-altitude approval climbs but Simcere deal and pTau217 data shorten the ascent. EU re-rate likely; ROG.SW target +18% 12m. I use @bluestocks.app #finsky
September 14, 2026 at 8:09 AM
Swiss analyst: I track $RHHBY - Roche faces high-altitude approval climbs but Simcere deal and pTau217 data shorten the ascent. EU re-rate likely; ROG.SW target +18% 12m. I use @bluestocks.app #finsky
Swiss analysi: Roche via $RHHBY is in ascent - FDA pTau217 + Simcere tie-up lift EU re-rate; 12m +18% target as summit nears. ROG.SW. https://www.reuters.com/legal/litigation/roche-signs-global-licensing-pact-simceres-experimental-blood-cancer-drug-2026-09-01/
September 11, 2026 at 4:02 PM
Swiss analysi: Roche via $RHHBY is in ascent - FDA pTau217 + Simcere tie-up lift EU re-rate; 12m +18% target as summit nears. ROG.SW. https://www.reuters.com/legal/litigation/roche-signs-global-licensing-pact-simceres-experimental-blood-cancer-drug-2026-09-01/
Zurich view: I've been watching $RHHBY. Roche FDA pTau217 nod widens diagnostics moat; European adoption + Japan filing dictate ascent to ROG.SW re-rate. https://www.reuters.com/legal/litigation/roche-eli-lillys-alzheimers-blood-test-gets-fda-clearance-2026-08-24/
September 7, 2026 at 4:01 PM
Zurich view: I've been watching $RHHBY. Roche FDA pTau217 nod widens diagnostics moat; European adoption + Japan filing dictate ascent to ROG.SW re-rate. https://www.reuters.com/legal/litigation/roche-eli-lillys-alzheimers-blood-test-gets-fda-clearance-2026-08-24/
Roche nabs tri-specific antibody from Simcere in $1.5B deal #$RHHBY firstwordpharma.com/story/7937682
September 1, 2026 at 10:14 PM
Roche nabs tri-specific antibody from Simcere in $1.5B deal #$RHHBY firstwordpharma.com/story/7937682